The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
Identifieur interne : 000032 ( Main/Corpus ); précédent : 000031; suivant : 000033The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
Auteurs : Marjan J. Meijboom ; Josien Riphagen-Dalhuisen ; Eelko HakSource :
- Influenza and other respiratory viruses [ 1750-2659 ] ; 2018.
English descriptors
- KwdEn :
- Cost-Benefit Analysis (MeSH), Health Personnel (MeSH), Humans (MeSH), Immunization Programs (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Models, Economic (MeSH), Netherlands (epidemiology), Vaccination (economics).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Netherlands.
- economics : Influenza, Human, Vaccination.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Cost-Benefit Analysis, Health Personnel, Humans, Immunization Programs, Models, Economic.
Abstract
BACKGROUND
Despite the clinical evidence, influenza vaccination coverage of healthcare workers remains low. To assess the health economic value of implementing an influenza immunization program among healthcare workers (HCW) in University Medical Centers (UMCs) in the Netherlands, a cost-benefit model was developed using a societal perspective.
METHODS/PATIENTS
The model was based on a trial performed among all UMCs in the Netherlands that included both hospital staff and patients admitted to the pediatrics and internal medicine departments. The model structure and parameters estimates were based on the trial and complemented with literature research, and the impact of uncertainty explored with sensitivity analyses.
RESULTS
In a base-case scenario without vaccine coverage, influenza-related annual costs were estimated at € 410 815 for an average UMC with 8000 HCWs and an average occupancy during the influenza period of 6000 hospitalized patients. Of these costs, 82% attributed to the HCWs and 18% were patient-related. With a vaccination coverage of 15.47%, the societal program's savings were € 2861 which corresponds to a saving of € 270.53 per extended hospitalization. Univariate sensitivity analyses show that the results are most sensitive to changes in the model parameters vaccine effectiveness in reducing influenza-like illness (ILI) and the vaccination-related costs.
CONCLUSION
In addition to the decreased burden of patient morbidity among hospitalized patients, the effects of the hospital immunization program slightly outweigh the economic investments. These outcomes may support healthcare policymakers' recommendations about the influenza vaccination program for healthcare workers.
DOI: 10.1111/irv.12558
PubMed: 29624882
PubMed Central: PMC6005606
Links to Exploration step
pubmed:29624882Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The potential economic value of influenza vaccination for healthcare workers in The Netherlands.</title><author><name sortKey="Meijboom, Marjan J" sort="Meijboom, Marjan J" uniqKey="Meijboom M" first="Marjan J" last="Meijboom">Marjan J. Meijboom</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Riphagen Dalhuisen, Josien" sort="Riphagen Dalhuisen, Josien" uniqKey="Riphagen Dalhuisen J" first="Josien" last="Riphagen-Dalhuisen">Josien Riphagen-Dalhuisen</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Hak, Eelko" sort="Hak, Eelko" uniqKey="Hak E" first="Eelko" last="Hak">Eelko Hak</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29624882</idno><idno type="pmid">29624882</idno><idno type="doi">10.1111/irv.12558</idno><idno type="pmc">PMC6005606</idno><idno type="wicri:Area/Main/Corpus">000032</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000032</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The potential economic value of influenza vaccination for healthcare workers in The Netherlands.</title><author><name sortKey="Meijboom, Marjan J" sort="Meijboom, Marjan J" uniqKey="Meijboom M" first="Marjan J" last="Meijboom">Marjan J. Meijboom</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Riphagen Dalhuisen, Josien" sort="Riphagen Dalhuisen, Josien" uniqKey="Riphagen Dalhuisen J" first="Josien" last="Riphagen-Dalhuisen">Josien Riphagen-Dalhuisen</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Hak, Eelko" sort="Hak, Eelko" uniqKey="Hak E" first="Eelko" last="Hak">Eelko Hak</name><affiliation><nlm:affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Influenza and other respiratory viruses</title><idno type="eISSN">1750-2659</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cost-Benefit Analysis (MeSH)</term><term>Health Personnel (MeSH)</term><term>Humans (MeSH)</term><term>Immunization Programs (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Models, Economic (MeSH)</term><term>Netherlands (epidemiology)</term><term>Vaccination (economics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Health Personnel</term><term>Humans</term><term>Immunization Programs</term><term>Models, Economic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Despite the clinical evidence, influenza vaccination coverage of healthcare workers remains low. To assess the health economic value of implementing an influenza immunization program among healthcare workers (HCW) in University Medical Centers (UMCs) in the Netherlands, a cost-benefit model was developed using a societal perspective.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS/PATIENTS</b></p><p>The model was based on a trial performed among all UMCs in the Netherlands that included both hospital staff and patients admitted to the pediatrics and internal medicine departments. The model structure and parameters estimates were based on the trial and complemented with literature research, and the impact of uncertainty explored with sensitivity analyses.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>In a base-case scenario without vaccine coverage, influenza-related annual costs were estimated at € 410 815 for an average UMC with 8000 HCWs and an average occupancy during the influenza period of 6000 hospitalized patients. Of these costs, 82% attributed to the HCWs and 18% were patient-related. With a vaccination coverage of 15.47%, the societal program's savings were € 2861 which corresponds to a saving of € 270.53 per extended hospitalization. Univariate sensitivity analyses show that the results are most sensitive to changes in the model parameters vaccine effectiveness in reducing influenza-like illness (ILI) and the vaccination-related costs.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In addition to the decreased burden of patient morbidity among hospitalized patients, the effects of the hospital immunization program slightly outweigh the economic investments. These outcomes may support healthcare policymakers' recommendations about the influenza vaccination program for healthcare workers.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29624882</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>The potential economic value of influenza vaccination for healthcare workers in The Netherlands.</ArticleTitle><Pagination><MedlinePgn>457-464</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.12558</ELocationID><Abstract><AbstractText Label="BACKGROUND">Despite the clinical evidence, influenza vaccination coverage of healthcare workers remains low. To assess the health economic value of implementing an influenza immunization program among healthcare workers (HCW) in University Medical Centers (UMCs) in the Netherlands, a cost-benefit model was developed using a societal perspective.</AbstractText><AbstractText Label="METHODS/PATIENTS">The model was based on a trial performed among all UMCs in the Netherlands that included both hospital staff and patients admitted to the pediatrics and internal medicine departments. The model structure and parameters estimates were based on the trial and complemented with literature research, and the impact of uncertainty explored with sensitivity analyses.</AbstractText><AbstractText Label="RESULTS">In a base-case scenario without vaccine coverage, influenza-related annual costs were estimated at € 410 815 for an average UMC with 8000 HCWs and an average occupancy during the influenza period of 6000 hospitalized patients. Of these costs, 82% attributed to the HCWs and 18% were patient-related. With a vaccination coverage of 15.47%, the societal program's savings were € 2861 which corresponds to a saving of € 270.53 per extended hospitalization. Univariate sensitivity analyses show that the results are most sensitive to changes in the model parameters vaccine effectiveness in reducing influenza-like illness (ILI) and the vaccination-related costs.</AbstractText><AbstractText Label="CONCLUSION">In addition to the decreased burden of patient morbidity among hospitalized patients, the effects of the hospital immunization program slightly outweigh the economic investments. These outcomes may support healthcare policymakers' recommendations about the influenza vaccination program for healthcare workers.</AbstractText><CopyrightInformation>© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meijboom</LastName><ForeName>Marjan J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9489-7802</Identifier><AffiliationInfo><Affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riphagen-Dalhuisen</LastName><ForeName>Josien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hak</LastName><ForeName>Eelko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit of PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01481467</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">economic value</Keyword><Keyword MajorTopicYN="Y">healthcare workers</Keyword><Keyword MajorTopicYN="Y">hospital</Keyword><Keyword MajorTopicYN="Y">implementation</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">patients</Keyword><Keyword MajorTopicYN="Y">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29624882</ArticleId><ArticleId IdType="doi">10.1111/irv.12558</ArticleId><ArticleId IdType="pmc">PMC6005606</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Euro Surveill. 2010 Nov 04;15(44):null</Citation><ArticleIdList><ArticleId IdType="pubmed">21087586</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2000 Jul;21(7):449-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10926394</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Jan;58(1):58-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24046312</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2002 Oct;23(10):615-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12400893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2009 Jul 24;84(30):301-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19630186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2000 Jan 8;355(9198):93-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10675165</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1999 Mar 10;281(10):908-13</Citation><ArticleIdList><ArticleId IdType="pubmed">10078487</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2000 Nov;21(11):730-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11089659</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2016 Sep 30;65(38):1026-31</Citation><ArticleIdList><ArticleId IdType="pubmed">27684642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2002 Mar;2(3):145-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11944184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2009 Jun;58(6):446-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19446340</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2013 May 23;13:235</Citation><ArticleIdList><ArticleId IdType="pubmed">23701921</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2003 Jun;8(6):130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Nov 21;34(48):5845-5854</Citation><ArticleIdList><ArticleId IdType="pubmed">27793486</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2015 Oct;136(4):809-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26347432</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010 Jun 02;340:c2509</Citation><ArticleIdList><ArticleId IdType="pubmed">20519267</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2008;26(11):911-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18850761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6353-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19840672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2016 Jun 02;(6):CD005187</Citation><ArticleIdList><ArticleId IdType="pubmed">27251461</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Nurs Rev. 2012 Jun;59(2):161-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22591085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ned Tijdschr Geneeskd. 2010;154:A1188</Citation><ArticleIdList><ArticleId IdType="pubmed">20977784</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2014 Feb;35(2):169-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24442080</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1997 Jan;175(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8985189</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Nov 28;29(51):9557-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21964058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 1999 Sep;18(9):779-83</Citation><ArticleIdList><ArticleId IdType="pubmed">10493337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2009 Sep;57(9):1580-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19682118</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2017 Jan 9;12 (1):e0169528</Citation><ArticleIdList><ArticleId IdType="pubmed">28068386</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 19;27(44):6261-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19686690</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Jul 12;28(31):5049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20493819</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Control Hosp Epidemiol. 2004 Nov;25(11):923-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15566025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Nov 16;23(46-47):5365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16029916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ned Tijdschr Geneeskd. 2014;158:A7650</Citation><ArticleIdList><ArticleId IdType="pubmed">25308221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010 Jul 07;(7):CD001269</Citation><ArticleIdList><ArticleId IdType="pubmed">20614424</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1996 Nov 16;313(7067):1241-2</Citation><ArticleIdList><ArticleId IdType="pubmed">8939114</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Dec 16;29(2):344-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20937313</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2006 Dec 16;333(7581):1241</Citation><ArticleIdList><ArticleId IdType="pubmed">17142257</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Jan;58(1):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24046301</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2009 Feb 1;48(3):292-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19115970</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2015 Sep 18;64(36):993-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26389743</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013 Jun 27;18(26):20512</Citation><ArticleIdList><ArticleId IdType="pubmed">23827527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000032 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000032 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:29624882
|texte= The potential economic value of influenza vaccination for healthcare workers in The Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:29624882" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |